Maxcyte Inc (MXCT)

Nov 18, 2024

MaxCyte stock touches 52-week low at $3.23 amid market challenges - Investing.com

Nov 18, 2024

Nov 15, 2024

Will MaxCyte's Q2 Results Surpass Market Expectations? - RTTNews

Nov 15, 2024

Nov 13, 2024

CADIAN CAPITAL MANAGEMENT, LP Expands Stake in MaxCyte Inc - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics - News-Medical.Net

Nov 13, 2024

Nov 13, 2024

MaxCyte Celebrates 25 Years - Baystreet.ca

Nov 13, 2024

Nov 13, 2024

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics - The Manila Times

Nov 13, 2024

Nov 13, 2024

MaxCyte Marks 25 Years of Innovation with Groundbreaking Cell Therapy Breakthrough | MXCT Stock News - StockTitan

Nov 13, 2024

Nov 11, 2024

MaxCyte stock touches 52-week low at $3.27 amid market shifts - Investing.com Canada

Nov 11, 2024

Nov 11, 2024

MaxCyte stock touches 52-week low at $3.27 amid market shifts By Investing.com - Investing.com South Africa

Nov 11, 2024

Nov 11, 2024

500: Something went wrong - Investing.com

Nov 11, 2024

Nov 11, 2024

FY2024 Earnings Estimate for MaxCyte Issued By William Blair - MarketBeat

Nov 11, 2024

Nov 09, 2024

MaxCyte, Inc. (NASDAQ:MXCT) Q3 2024 Earnings Call Transcript - MSN

Nov 09, 2024

Nov 08, 2024

MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 08, 2024

Nov 07, 2024

MaxCyte Files Quarterly Report, Highlights Financial Progress - TipRanks

Nov 07, 2024

Nov 07, 2024

MaxCyte’s Revenue Grows and Strategic Moves Unveiled - TipRanks

Nov 07, 2024

Nov 07, 2024

Investors ignore increasing losses at MaxCyte (LON:MXCT) as stock jumps 10% this past week - Simply Wall St

Nov 07, 2024

Nov 06, 2024

MaxCyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024

Nov 06, 2024

Constellation Energy Corp (CEG-Q) QuotePress Release - The Globe and Mail

Nov 06, 2024

Nov 06, 2024

MaxCyte Director Sells Shares Amid Active Trading - TipRanks

Nov 06, 2024

Nov 06, 2024

Goldman Sachs Group (GS-N) QuotePress Release - The Globe and Mail

Nov 06, 2024

Nov 04, 2024

MaxCyte Expands Stock Capital with New Issuance - TipRanks

Nov 04, 2024

Nov 01, 2024

MaxCyte (LON:MXCT) Stock Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat

Nov 01, 2024

Oct 31, 2024

MaxCyte to Participate in Two Upcoming Investor Conferences - StockTitan

Oct 31, 2024

Oct 31, 2024

MaxCyte to Join Key Investor Conferences in November - TipRanks

Oct 31, 2024

Oct 31, 2024

MaxCyte’s Insider Stock Activity in Focus - TipRanks

Oct 31, 2024

Oct 30, 2024

MaxCyte director Johnston sells $11,166 in stock - Investing.com

Oct 30, 2024

Oct 30, 2024

Overcome the limitations of conventional transfection with MaxCyte Electroporation - LabRoots

Oct 30, 2024

Oct 30, 2024

MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company - Yahoo Finance

Oct 30, 2024

Oct 30, 2024

MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2024

Oct 18, 2024

Grant of Options and Restricted Stock Units - ShareCast

Oct 18, 2024

Oct 18, 2024

MaxCyte Awards Stock Options to Boost Growth - TipRanks

Oct 18, 2024

Oct 16, 2024

MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Oct 16, 2024

Oct 15, 2024

MaxCyte Appoints Cynthia Collins to its Board of Directors - ForexTV.com

Oct 15, 2024

Oct 15, 2024

MaxCyte Strengthens Board with Cynthia Collins Appointment - TipRanks

Oct 15, 2024

Oct 12, 2024

MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer - Head Topics

Oct 12, 2024

Oct 11, 2024

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 - ForexTV.com

Oct 11, 2024

Oct 11, 2024

MaxCyte to Unveil Q3 2024 Financial Results - TipRanks

Oct 11, 2024

Oct 10, 2024

People on the Move: Ali Soleymannezhad, Chief Commercial Officer, MaxCyte - BioBuzz

Oct 10, 2024

Oct 10, 2024

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer - citybiz

Oct 10, 2024

Oct 10, 2024

MaxCyte appoints new chief commercial officer - ShareCast

Oct 10, 2024

Oct 10, 2024

MaxCyte appoints Soleymannezhad as CCO - TipRanks

Oct 10, 2024

Oct 10, 2024

MaxCyte Names New CCO for Market Expansion - TipRanks

Oct 10, 2024

Oct 10, 2024

MaxCyte upgraded to Buy from Hold at Deutsche Bank - TipRanks

Oct 10, 2024

Oct 05, 2024

Marshall Wace LLP Acquires New Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat

Oct 05, 2024

Oct 04, 2024

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up (NASDAQ:MXCT) - Seeking Alpha

Oct 04, 2024

Oct 03, 2024

Stan Erck Sells 47,689 Shares of MaxCyte, Inc. (LON:MXCT) Stock - MarketBeat

Oct 03, 2024

Oct 03, 2024

MaxCyte, Inc. (LON:MXCT) Insider Sells £185,033.32 in Stock - Defense World

Oct 03, 2024

Oct 03, 2024

MaxCyte Director Executes Stock Options Sale - TipRanks

Oct 03, 2024

Oct 02, 2024

MaxCyte director Stanley Erck sells shares worth over $178k - Investing.com

Oct 02, 2024

Oct 02, 2024

MaxCyte director Stanley Erck sells shares worth over $178k By Investing.com - Investing.com Australia

Oct 02, 2024

Oct 02, 2024

MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $80,161.97 in Stock - MarketBeat

Oct 02, 2024